955 completed, 315 terminated, 248 recruiting, 199 unknown. 2037 Phase 2, 588 Phase 1, 76 Phase 3.
Follow Leukemia, Myeloid: new trials by email Literature Review of Leukemia, Myeloid trials Research Report on Leukemia, Myeloid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pyronaridine in Acute Myeloid Leukemia (AML) Pyronaridine Tetraphosphate - Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | Phase 2 | Suspended | Armaceutica, Inc. | 200 | 2028-02-21 | 2026-10-19 |
| A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML) Cytarabine, Oral Cladribine - Acute Myeloid Leukemia (AML) | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 58 | 2027-12-01 | 2026-08-25 |
| Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 122 | 2027-01-15 | 2026-10-07 |
| Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Biopsy - Acute Myeloid Leukemia | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 244 | 2027-01-15 | 2026-10-20 |
| Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) Azacitidine, Bone Marrow Aspiration and Biopsy, Cytarabine - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 184 | 2027-01-04 | 2026-10-01 |
| CD34+ Transplants for Myeloid Malignancies Busulfan, Melphalan, Fludarabine - Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute | Phase 2 | Not yet recruiting | Guenther Koehne | 50 | 2027-01-01 | 2026-10-13 |
| Asciminib Frontline Risk Adapted Dasatinib 80mg QD (5 days per week), Standarc of Care - Chronic Myeloid Leukemia (CML) | Phase 2 | Not yet recruiting | Prof. Dr. med. Andreas Hochhaus | 200 | 2027-01-01 | 2026-09-04 |
| GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors VTRU200 - Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Vitruviae | 108 | 2027-01-01 | 2026-08-06 |
| Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative Neoplasms Oral THU-decitabine - Myelofibrosis, MPN - Accelerated or Blast Phase | Phase 2 | Not yet recruiting | John Mascarenhas | 20 | 2027-01-01 | 2026-10-14 |
| Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 52 | 2027-01-01 | 2026-09-14 |
| Multi-CAR T Cell Therapy for Acute Myeloid Leukemia Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 10 | 2026-12-31 | 2026-08-26 |
| A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloid Leukemia CAV - Acute Myeloid Leukemia (AML) | Phase 2 | Not yet recruiting | University of Rochester | 24 | 2026-12-31 | 2026-10-16 |
| Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies CD7-specific CAR gene-engineered T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2026-12-31 | 2026-08-26 |
| A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia sonrotoclax, Azacitidine, Inotuzumab ozogamicin - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | BeOne Medicines | 30 | 2026-12-01 | 2026-10-26 |
| Menin-Inhibitor Targeted Maintenance in AML Revumenib, Placebo - Relapsed Adult AML, Stem Cell Transplant Complications | Phase 2 | Not yet recruiting | Center for International Blood and Marrow Transplant Research | 146 | 2026-12-01 | 2026-06-22 |
| Geriatric Assessment-Guided Treatment Selection in Older Adults With Acute Myeloid Leukemia GA-directed treatment regimens - Acute Myeloid Leukemia | Phase 2 | Not yet recruiting | University of Rochester | 120 | 2026-12-01 | 2026-07-29 |
| A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant Maintenance Therapy, No intervention - Myeloid Disorders, Myelodysplastic Syndromes | Phase 2 | Not yet recruiting | Medical College of Wisconsin | 450 | 2026-12-01 | 2026-10-13 |
| Mitoxantrone Hydrochloride Liposome Combined With Cladribine And Sotorasib For Relapsed Refractory Acute Myeloid Leukemia Mitoxantrone Hydrochloride Liposome+cladribine+sotoraclib - Relapsed and Refractory Acute Myeloid Leukemia (RR-AML) | Phase 2 | Not yet recruiting | The Affiliated People's Hospital of Ningbo University | 20 | 2026-12-01 | 2026-10-15 |
| FLT3-ITD Targeted Therapy in Fit AML Patients Gilteritinib, Venetoclax, Azacitidine (AZA) - AML (Acute Myeloid Leukemia) | Phase 2 / Phase 3 | Not yet recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 230 | 2026-12-01 | 2026-02-23 |
| Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML Fludarabine, Cytarabine, Idarubicin - Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 30 | 2026-11-30 | 2026-10-13 |
Showing 20 of 2037. Sign in to see all of them.
Leukemia, Myeloid, Acute (1553) · Myelodysplastic Syndromes (639) · Leukemia (493) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (430) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (404) · Leukemia, Myelomonocytic, Chronic (264) · Lymphoma, Non-Hodgkin (211) · Leukemia, Myeloid, Chronic-Phase (210) · Myeloproliferative Disorders (197) · Leukemia, Lymphocytic, Chronic, B-Cell (195) · Hodgkin Disease (187) · Congenital Abnormalities (171) · Multiple Myeloma (170) · Blast Crisis (159) · Recurrence (157)
Hemic and Lymphatic Diseases (2037) · Neoplasms by Histologic Type (2031) · Hematologic Diseases (2007) · Neoplasms (1995) · Leukemia (1544) · Bone Marrow Diseases (1144) · Pathological Conditions, Signs and Symptoms (931) · Pathologic Processes (925) · Disease Attributes (902) · Chronic Disease (801) · Myeloproliferative Disorders (561) · Immune System Diseases (548) · Immunoproliferative Disorders (523) · Lymphatic Diseases (518)
Cytarabine (328) · Azacitidine (255) · Cyclophosphamide (214) · fludarabine phosphate (190) · venetoclax (186) · fludarabine (154) · Busulfan (151) · Mycophenolic Acid (122) · Peripheral Blood Stem Cell Transplantation (122) · Decitabine (117) · Tacrolimus (117) · Whole-Body Irradiation (116) · Filgrastim (101) · Cyclosporine (94) · Idarubicin (92)
M.D. Anderson Cancer Center (190) · Fred Hutchinson Cancer Center (103) · National Cancer Institute (NCI) (90) · Novartis Pharmaceuticals (44) · Masonic Cancer Center, University of Minnesota (43) · Memorial Sloan Kettering Cancer Center (42) · The First Affiliated Hospital of Soochow University (31) · City of Hope Medical Center (26) · Washington University School of Medicine (24) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (20) · National Heart, Lung, and Blood Institute (NHLBI) (19) · Case Comprehensive Cancer Center (17) · H. Lee Moffitt Cancer Center and Research Institute (17) · Roswell Park Cancer Institute (17) · Bristol-Myers Squibb (16)
United States (1270) · China (204) · France (179) · Germany (176) · Italy (149) · Canada (122) · Spain (110) · United Kingdom (99) · South Korea (71) · Australia (62) · Netherlands (60) · Belgium (56) · Poland (44) · Israel (42) · Russia (40)
Jorge Cortes, MD (17) · Brenda Sandmaier (13) · Farhad Ravandi-Kashani, MD (11) · Courtney DiNardo, MD (8) · Roland Walter (8) · Guillermo Garcia-Manero, MD (7) · Jorge E Cortes, MD (7) · Judith Karp (6) · Ann E. Woolfrey, MD (5) · Arnon Nagler, MD (5) · B. Douglas Smith, MD (5)
PMID 32499241, PMID 23524640, PMID 28835440, PMID 30885996, PMID 33394722, PMID 23065508, PMID 23620574, PMID 30062662, PMID 36184192, PMID 25361995, PMID 29702001, PMID 31171508, PMID 35007144, PMID 35235189, PMID 35982483, PMID 40073835, PMID 17715389, PMID 21527516, PMID 22133778, PMID 22158386, PMID 24383844, PMID 24719405, PMID 24862638, PMID 25527568, PMID 27355533, PMID 28054442, PMID 28877686, PMID 29618479, PMID 30028037, PMID 33741715, PMID 33917201, PMID 34267079, PMID 34797911, PMID 36054756, PMID 38507688, PMID 40513054, PMID 41621809, PMID 42013378, PMID 10204198, PMID 11015443, PMID 11034090, PMID 11313690, PMID 11331327, PMID 11585760, PMID 11756187, PMID 12242449, PMID 12651206, PMID 12721664, PMID 12750167, PMID 14603333
P30CA015704 (46), P01CA018029 (18), P30CA006973 (17), 2018 (15), U10CA031946 (14), 2023 (12), P30CA016672 (12), P30CA033572 (12), 2008 (11), P01CA078902 (11), P30CA043703 (11), U10CA032102 (11), 2014 (10), 2019 (10), 2025 (10)